Waldencast plc completed the sale of its Obagi Medical dermatological skincare and aesthetics business on July 30, 2026. Total consideration includes up to $366.0 million in cash, a fixed vendor note of $10.0 million, an adjustable vendor note of $20.0 million, and contingent earnout consideration of up to $64.0 million based on post-closing revenue milestones for 2026 and 2027. Waldencast utilized approximately $334.4 million in net proceeds to fully repay its outstanding senior term loan facility. Following the transaction, the company will operate as the parent of Milk Makeup, a clean prestige beauty brand. The filing includes unaudited pro forma financial statements reflecting this significant business disposition.

Waldencast plc completed the sale of its Obagi Medical dermatological skincare and aesthetics business to Bridgepoint on July 30, 2026. The transaction is valued at up to $460 million, comprising a fixed vendor note of $10 million, an adjustable vendor note of $20 million, and contingent earnout payments of up to $64 million based on revenue milestones through December 2027. Proceeds were used to repay all outstanding senior term loan facility debt. Founders Michel Brousset and Hind Sebti, along with CFO Manuel Manfredi, transitioned to lead Obagi Medical. Felipe Dutra was appointed Executive Chairman and will serve as principal executive and financial officer. Waldencast plc operates in the beauty industry, focusing on the global growth of its Milk Makeup brand.

Waldencast plc (NASDAQ: WALD) will hold its 2026 Annual General Meeting on 4 August 2026 in London, with a record date of 26 June 2026. Following the sale of Obagi Medical, directors Michel Brousset and Hind Sebti will resign, and Mazdack Rassi will be appointed to the Board as a Class II director effective at the meeting. Waldencast plc is a beauty brand parent company focusing on Milk Makeup.